Comparable bioavailability of two esophago-gastric protective formulations containing pamidronate. A cross-over trial in healthy young adults;Biodisponibilidad comparable de dos formulaciones gastroprotectoras que contienen pamidronato. Un estudio cruzado en voluntarios sanos

Medicina

Volumn 62, Issue 4, 2002, Pages 317-322

  Roldan, Emilio J A ^a   Quattrocchi, Oscar ^a   Zanchetta, Jose ^a   Plotkin, Horacio ^a   Araujo, Graciela ^a   Piccinni, Enrique ^a  

^a Gador SA   (Argentina)

Author keywords

Oral bisphosphonates; Pamidronate bioavailability

Indexed keywords

ACID; BISPHOSPHONIC ACID DERIVATIVE; CAS 57248 88 1; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; PAMIDRONIC ACID; PHOSPHATIDYLCHOLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG FORMULATION; ENTERIC COATED TABLET; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE MUCOSA; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; PROTECTIVE AGENTS;

EID: 0036382106     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Yakatan GJ, Poynor WJ, Talbert RL, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982; 31: 402-10.
2. 99mTc sodium olpadronate in patients with Paget's bone disease or osteoporosis. Eur J Clin Pharmacol 1995; 48: 489-94.
3. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporosis Int 1993; 3(suppl): S13- 16.
4. Roldán EJA, Quattrocchi O, Araujo G, Piccinni E. Aplicación clínica de los principios farmacocinéticos de los bisfosfonatos. Medicina (Buenos Aires) 1997; 57 (suppl): 76-82.
5. Lufkin EG, Argueta R, Whitaker MO, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994; 4: 320-2.
6. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Eng J Med 1997; 335: 1016-21.
7. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasché R, Roldán EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other bone diseases. Curr Ther Res 1996; 57: 123-30.
8. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis; a three-year randomized, placebo-controlled clinical trial with a two-year open extension. J Bone Miner Res. In press 2002.
9. Flesch G, Hauffe S. Determination of the bisphosphonate pamidronate disodium in urine by precolumn derivatization with Fluorescamine, HPLC and fluorescence detection. J Chromatograph 1991; 489: 446-51.
10. Flesch G, Tominaga N, Degen P. Improved determination of the bisphosphonate pamidronate disodium in plasma and urine by precolumn derivatization with Fluorescamine, HPLC and fluorescence detection. J Chromatograph 1991; 568: 261-6.
11. Stein S, Bohlen P, Dariman W, Underfriend S. Aminoacid analysis with fluorescamine at the picomole level. Arch Biochem Biophys 1973; 155: 619-22.
12. Bohlen P, Stein S, Daiman W, Underfriend S. Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys 1973; 155: 213-20.
13. St John P. Assay of amino acids, peptides, proteins and other primary amines with fluorescamine. Fluorescence News 1973; 7: 9-11.
14. Underfriend S, Stein S, Bohlen P, Daiman W. Fluorescamine: A reagent for assay of amino acids, peptides, proteins and primary amines in the picomole range. Science 1972; 178: 871-2.
15. Arnoux P, Morrison R.; Drug analysis of biological samples. A survey of validation approaches in chromatography in the UK pharmaceutical industry. Xenobiotica 1992; 22: 757-64.
16. -88 MDP as a bone scanning agent. J Nucl Med 1985; 26:1135-9.
17. Mönkkönen J, Koponen HM, Ylitalo P. Comparison of the distribution of three bisphosphonate in mice. Pharmacol Toxicol 1989; 65: 294-8.
18. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
19. Papapoulos SE, Landman JO, Bijvoet OLM, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13: A41-9.
20. Valkema R et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone and Mineral 1989; 5: 183-92.
21. Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1994; 1: 129-33.
22. Zanchetta JR, Spivacow RF, Bogado C, Sarli M, Plotkin H, Roldán EJA. Uso prolongado, hasta 6 años, de un aminobisfosfonato oral en pacientes con osteoporosis establecida. Medicina (Buenos Aires) 1997; 75 (suppl 1): 37-44.
23. Barreira JC, Messina OD, Maldonado Cocco JA, Roldán EJA. Site- dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: A preliminary report. Clin Rheumatol 1997; 16 (suppl 1): 346-52.
24. Hyldstrup L, Flesch G, Hauffe SA. Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcif Tissue Int 1996; 53: 297-300.